# Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

> **NCT03844061** · PHASE2 · RECRUITING · sponsor: **Hospital for Special Surgery, New York** · enrollment: 30 (estimated)

## Conditions studied

- Systemic Sclerosis

## Interventions

- **DRUG:** Belimumab
- **DRUG:** Rituximab
- **OTHER:** Placebo Subcutaneous Injection
- **OTHER:** Placebo Infusion
- **DRUG:** MMF

## Key facts

- **NCT ID:** NCT03844061
- **Lead sponsor:** Hospital for Special Surgery, New York
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-07-29
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03844061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03844061, "Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03844061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*